Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines

Authors:

Abstract
No abstract available
Funding Information
  • Taiho Pharmaceutical Co.
  • Taiho Pharmaceutical Co.
  • Taiho Pharmaceutical Co.
  • JSPS KAKENHI (JP19K07665)

This publication has 9 references indexed in Scilit: